Quture/TCLN Announces Formation of Subsidiary for European Operations
Company pursuing business opportunities with InterSystems Iberia and future expansion throughout Europe.
“The focus of Quture products in Europe will be slightly different because of the needs of hospitals and physicians,”
Formation of Quture Euro is an integral strategy of the Quture Management Team to align their respective skills, roles, and responsibilities within Quture International. A separate operations subsidiary in Europe is a key component of the global plan and competency of the Company.
“We are moving decisively to take advantage of the strength of our partner InterSystems in Europe. A subsidiary focused on Europe provides the Company with a significant array of business strategies and opportunities that are potentially of enormous valuable,” said Landon Feazell, Chairman & CEO of Quture International, Inc. “This is consistent with the plans of the Company to become the international standard in healthcare performance and outcomes measurement. Performance analytics is truly the international solution to improve care and reduce costs. It is not just an American solution, it is the global solution. We believe our QualOptima product will be a major force in the transformation of health care payment and delivery systems.”
QUTURE INTERNATIONAL, INC.
Quture International, Inc. is an emerging growth company positioned to become the leading clinical knowledge company in the world. The core competence of Quture is clinical performance enhancement to achieve optimal patient outcomes. Quture’s brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and health care while reducing costs, Quture is comprised of a subsidiaries in North America and Europe for the operations of its software technology solutions, plans for a “beyond data” consulting and knowledge applications company, as well as plans for a personalized, proactive, and predictive medicine company with a virtual community of members. These subsidiaries will all be affiliated with the Qx Medical Exchange, which the Company intends to become the largest medical and health exchange in the world. Quture International is a Nevada corporation currently trading under the symbol TCLN.
Quture, Inc. is the operations subsidiary of Quture International, Inc., positioned to become the international standard in health care performance, outcomes and analytics. Quture’s transformational product QualOptima operates on the InterSystems technology platform, the leading software platform globally for health care. QualOptima is the transcendent healthcare analytics system for performance enhancement to achieve optimal patient outcomes. The analytics system measures performance against evidence-based optimal clinical processes of care. The clinical data repository of QualOptima, the Qualytx integrated aggregate clinical database, is planned to become the international common data platform for health and health care. Qualytx will then be capable of transforming personal health and health care through knowledge solutions founded on Quture’s proprietary science of knowing what to measure, where that data resides in disparate databases, using the InterSystems technology to electronically abstract that data, and converting data to knowledge and actionable insight with its revolutionary and proprietary analytics system. As America transitions to payment for value and U.S. and international pressures converge to measure performance, Quture will navigate the future of global health and healthcare quality, patient safety and value.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.
For Further Information Contact:
Constellation Asset Advisors, Inc.
Jens Dalsgaard, President
+1 (415) 524-8500